FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Broderick

Research Profile

Chemicals & Drugs

Procedures

Disorders

Physiology

Platelet Aggregation

Devices

Stents

Concepts & Ideas

Co-author Network

Publications

TOP 3
Dean J Kereiakes; Joseph K Choo; John J Young; Thomas M Broderick
Thrombosis and drug-eluting stents: a critical appraisal.
Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
John J Young; Daniel P Marcus; Charles W Abbottsmith; Thomas M Broderick; Joseph K Choo; John Paul Runyon; John F Schneider; Thomas M Shimshak; Rodney P Geier; Dean J Kereiakes
Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Broderick (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: Dean J Kereiakes; Joseph K Choo; John J Young; Thomas M Broderick
Thrombosis and drug-eluting stents: a critical appraisal.
Reviews in cardiovascular medicine 2004;5(1):9-15.
2003: Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
American heart journal 2003;145(2):e6.
2003: John J Young; Daniel P Marcus; Charles W Abbottsmith; Thomas M Broderick; Joseph K Choo; John Paul Runyon; John F Schneider; Thomas M Shimshak; Rodney P Geier; Dean J Kereiakes
Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice.
The Journal of invasive cardiology 2003;15 Suppl A():9A-13A.
2002: Dean J Kereiakes; John J Young; Joseph K Choo; Thomas M Broderick
Intragraft verapamil: an ounce of prevention is worth a pound of cure.
The Journal of invasive cardiology 2002;14(6):303-4.
2002: Dean J Kereiakes; Joseph K Choo; John J Young; Thomas M Broderick
Combination antiplatelet therapy following brachytherapy with restenting: it ain't over 'til the fat lady sings.
The Journal of invasive cardiology 2002;14(3):115-7.
2002: Dean J Kereiakes; Thomas M Broderick; Wendy L Howard; Linda C Anderson; Mark Weber; Donald L Mitts
Successful long-term therapy following saphenous vein-covered stent deployment for atherosclerotic coronary aneurysm.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2002;55(1):100-4.
2001: Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; K Pieper; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
American heart journal 2001;142(5):790-8.
2001: David E Kandzari; Victor S Behar; Michael H Sketch; Dean J Kereiakes; Thomas M Shimshak; Thomas M Broderick; J Young; John Paul Runyon; R D Safian; M Kern; A Colombo
Extensive thrombus prior to elective percutaneous coronary intervention.
The Journal of invasive cardiology 2001;13(7):538-42.
2001: Dean J Kereiakes; Cindy L Grines; Edward T A Fry; P Esente; D Hoppensteadt; Mark G Midei; L Barr; W Matthai; M Todd; Thomas M Broderick; R Rubinstein; J Fareed; E Santoian; A Neiderman; Bruce R Brodie; James Zidar; James J Ferguson; Marc Cohen
Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.
The Journal of invasive cardiology 2001;13(4):272-8.
2001: E J Dippel; Dean J Kereiakes; D A Tramuta; Thomas M Broderick; Thomas M Shimshak; EM Roth; CR Hattemer; John Paul Runyon; DD Whang; John F Schneider; Charles W Abbottsmith
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2001;52(3):279-86.
2001: Dean J Kereiakes; N S Kleiman; Edward T A Fry; G Mwawasi; R Lengerich; K Maresh; M L Burkert; J W Aquilina; M DeLoof; Thomas M Broderick; Thomas M Shimshak
Dalteparin in combination with abciximab during percutaneous coronary intervention.
American heart journal 2001;141(3):348-52.
2000: Dean J Kereiakes; J Young; Thomas M Broderick; Thomas M Shimshak; Charles W Abbottsmith
Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes.
The American journal of cardiology 2000;86(12B):10M-17M.
2000: Dean J Kereiakes; Robert Obenchain; B L Barber; A Smith; M McDonald; Thomas M Broderick; John Paul Runyon; Thomas M Shimshak; John F Schneider; CR Hattemer; EM Roth; DD Whang; D Cocks; Charles W Abbottsmith
Abciximab provides cost-effective survival advantage in high-volume interventional practice.
American heart journal 2000;140(4):603-10.
2000: Dean J Kereiakes; TJ Linnemeier; Donald S Baim; Richard Kuntz; Charles O'Shaughnessy; James Hermiller; Stanley Fink; Alexandra Lansky; N Nishimura; Thomas M Broderick; Jeffrey J Popma
Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials).
The American journal of cardiology 2000;86(3):336-41.
2000: Dean J Kereiakes; John Paul Runyon; Thomas M Broderick; Thomas M Shimshak
IIb's are not IIb's.
The American journal of cardiology 2000;85(8A):23C-31C.
2000: Dean J Kereiakes; Edward T A Fry; W Matthai; A Niederman; L Barr; Bruce R Brodie; James Zidar; P Casale; G Christy; D Moliterno; R Lengerich; Thomas M Broderick; Thomas M Shimshak; Marc Cohen
Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".
The Journal of invasive cardiology 2000;12 Suppl A():1A-5A.
2000: Dean J Kereiakes; Thomas M Broderick; Charles W Abbottsmith; Thomas M Shimshak
Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.
The Journal of invasive cardiology 2000;12(2):95-8.
2000: Dean J Kereiakes; M McDonald; Thomas M Broderick; EM Roth; DD Whang; L H Martin; Wendy L Howard; J Schneider; Thomas M Shimshak; Charles W Abbottsmith
Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
American heart journal 2000;139(2 Pt 2):S53-60.
2000: Dean J Kereiakes; Thomas M Broderick; EM Roth; DD Whang; M Mueller; P Lacock; Linda C Anderson; Wendy L Howard; C Blanck; J Schneider; C A Abbottsmith
High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Journal of thrombosis and thrombolysis 2000;9(2):149-55.
2000: D A Tramuta; Dean J Kereiakes; E J Dippel; R Lengerich; Thomas M Broderick; Charles W Abbottsmith; DD Whang; EM Roth; John F Schneider; Wendy L Howard; Thomas M Shimshak
Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?
The Journal of invasive cardiology 2000;12 Suppl C():3C-6C.
1999: Dean J Kereiakes; Mark G Midei; James Hermiller; Charles O'Shaughnessy; R Schlofmitz; Steven Yakubov; Stanley Fink; F Hu; N Nishimura; M Sievers; M E Valentine; Thomas M Broderick; Alexandra Lansky; Jeffrey Moses
Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment.
The American journal of cardiology 1999;84(12):1385-90.
1999: Dean J Kereiakes; Thomas M Broderick; EM Roth; DD Whang; Thomas M Shimshak; John Paul Runyon; CR Hattemer; J Schneider; P Lacock; M Mueller; Charles W Abbottsmith
Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
The American journal of cardiology 1999;84(4):391-5.
1999: Dean J Kereiakes; M Mueller; Wendy L Howard; P Lacock; Linda C Anderson; Thomas M Broderick; EM Roth; DD Whang; Charles W Abbottsmith
Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
Journal of thrombosis and thrombolysis 1999;7(3):265-76.
1998: Dean J Kereiakes; N S Kleiman; J J Ferguson; A R Masud; Thomas M Broderick; Charles W Abbottsmith; John Paul Runyon; Linda C Anderson; R J Anders; R J Dreiling; G L Hantsbarger; B Bryzinski; Eric J Topol
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
Circulation 1998;98(13):1268-78.
1997: Dean J Kereiakes; Thomas M Broderick; DD Whang; L Anderson; D Fye
Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention.
The American journal of cardiology 1997;80(5):633-4.
1997: Dean J Kereiakes; N Kleiman; J J Ferguson; John Paul Runyon; Thomas M Broderick; N A Higby; L H Martin; G Hantsbarger; S McDonald; R J Anders
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Circulation 1997;96(4):1117-21.
1996: Dean J Kereiakes; J H Essell; Charles W Abbottsmith; Thomas M Broderick; John Paul Runyon
Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion.
The American journal of cardiology 1996;78(10):1161-3.